Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 286, Issue 4 55-4, 2004, Pages

  LaPointe, Margot C ^a   Mendez, Mariela ^a   Leung, Alicia ^a   Tao, Zhenyin ^a   Yang, Xiao Ping ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Collagen; Echocardiography; Nonsteroidal anti inflammatory drugs; NS 398; Prostanoids

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; COLLAGEN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; MESSENGER RNA; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; ROFECOXIB; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; FIBROBLAST; HEART EJECTION FRACTION; HEART FUNCTION; HEART HYPERTROPHY; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE CONTRACTION; HEART OUTPUT; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INFLAMMATORY CELL; LEFT ANTERIOR DESCENDING CORONARY ARTERY; M MODE ECHOCARDIOGRAPHY; MALE; MOUSE; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CARDIOMEGALY; COLLAGEN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; ECHOCARDIOGRAPHY; FIBROSIS; HEART; IMMUNOHISTOCHEMISTRY; ISOENZYMES; LACTONES; MALE; MICE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; NITROBENZENES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFONAMIDES; SULFONES; TRANSFORMING GROWTH FACTOR BETA;

EID: 1642289000     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00136.2003     Document Type: Article

References (51)

1. Adams JW, Migita DS, Yu MK, Young R, Hellickson MS, Castro-Vargas FE, Domingo JD, Lee PH, Bui JS, and Henderson SA. Prostaglandin F2 alpha stimulates hypertrophic growth of cultured neonatal rat ventricular myocytes. J Biol Chem 271: 1179-1186, 1996.
2. Agha AM, El Khatib AS, and Al Zuhair H. Modulation of oxidant status by meloxicam in experimentally induced arthritis. Pharmacol Res 40: 385-392, 1999.
3. Bennett A and Villa G. Nimesulide: an NSAID that preferentially inhibits COX-2, and has various unique pharmacological activities. Expert Opin Pharmacother 1: 277-286, 2000.
4. Bolli R, Goldstein RE, Davenport N, and Epstein SE. Influence of sulfinpyrazone and naproxen on infarct size in the dog. Am J Cardiol 47: 841-847, 1981.
5. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, and the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343: 1520-1530, 2000.
6. Bonow RO, Lipson LC, Sheehan FH, Capurro NL, Isner JM, Roberts WC, Goldstein RE, and Epstein SE. Lack of effect of aspirin on myocardial infarct size in the dog. Am J Cardiol 47: 258-264, 1981.
7. Chenevard R, Hurlimann D, Bechir M, Enseleit F, Spieker L, Hermann M, Riesen W, Gay S, Gay RE, Neidhart M, Michel B, Luscher TF, Noll G, and Ruschitzka F. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 107: 405-409, 2003.
8. Cheng HF, Wang CJ, Moeckel GW, Zhang MZ, McKanna JA, and Harris RC. Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int 62: 929-939, 2002.
9. 2. Science 296: 539-541, 2002.
10. 2-dependent plaque instability. Circulation 104: 921-927, 2001.
11. Domoki F, Veltkamp R, Thrikawala N, Robins G, Bari F, Louis TM, and Busija DW. Ischemia-reperfusion rapidly increases COX-2 expression in piglet cerebral arteries. Am J Physiol Heart Circ Physiol 277: H1207-H1214, 1999.
12. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, and Lipsky PE. Cyclooxygenase in biology and disease. FASEB J 12: 1063-1073, 1998.
13. Harding P, Sigmon DH, Alfie ME, Huang PL, Fishman MC, Beierwaltes WH, and Carretero OA. Cyclooxygenase-2 mediates increased renal renin content induced by low-sodium diet. Hypertension 29: 297-302, 1997.
14. Harris RC. Cyclooxygenase-2 in the kidney. J Am Soc Nephrol 11: 2387-2394, 2000.
15. He Q, Wang D, Yang XP, Carretero OA, and LaPointe MC. Inducible regulation of the human BNP promoter in transgenic mice. Am J Physiol Heart Circ Physiol 280: H368-H376, 2001.
16. Hocherl K, Dreher F, Kurtz A, and Bucher M. Cyclooxygenase-2 inhibition attenuates lipopolysaccharide-induced cardiovascular failure. Hypertension 40: 947-953, 2002.
17. Iadecola C, Niwa K, Nogawa S, Zhao X, Nagayama M, Araki E, Morham S, and Ross ME. Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci USA 98: 1294-1299, 2001.
18. Jugdutt BI, Hutchins GM, Bulkley BH, and Becker LC. Salvage of ischemic myocardium by ibuprofen during infarction in the conscious dog. Am J Cardiol 46: 74-82, 1980.
19. Koistinaho J and Chan PH. Spreading depression-induced cyclooxygenase-2 expression in the cortex. Neurochem Res 25: 645-651, 2000.
20. 2α induces cardiac myocyte hypertrophy in vitro and cardiac growth in vivo. Am J Physiol Heart Circ Physiol 271: H2197-H2208, 1996.
21. Linssen MC, Engels W, Lemmens PJ, Heijnen VV, Van Bilsen M, Reneman RS, and van der Vusse GJ. Production of arachidonic acid metabolites in adult rat cardiac myocytes, endothelial cells, and fibroblast-like cells. Am J Physiol Heart Circ Physiol 264: H973-H982, 1993.
22. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, and Carretero OA. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 99: 1926-1935, 1997.
23. Manabe I, Shindo T, and Nagai R. Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res 91: 1103-1113, 2002.
24. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 52: 5575-5589, 1992.
25. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, Isakson PC, and Seibert K. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 91: 3228-3232, 1994.
26. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, and FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 96: 272-277, 1999.
27. 2 in cardiac myocytes. Hypertension 39: 382-388, 2002.
28. Mukherjee D, Nissen SE, and Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286: 954-959, 2001.
29. Mullane KM, Read N, Salmon JA, and Moncada S. Role of leukocytes in acute myocardial infarction in anesthetized dogs: relationship to myocardial salvage by anti-inflammatory drugs. J Pharmacol Exp Ther 228: 510-522, 1984.
30. 2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 275: 32783-32792, 2000.
31. Nagayama M, Niwa K, Nagayama T, Ross ME, and Iadecola C. The cyclooxygenase-2 inhibitor NS-398 ameliorates ischemic brain injury in wild-type mice but not in mice with deletion of the inducible nitric oxide synthase gene. J Cereb Blood Flow Metab 19: 1213-1219, 1999.
32. Noguchi K, Iwasaki K, and Ishikawa I. Prostaglandin F2 alpha upregulates intercellular adhesion molecule-1 expression in human gingival fibroblasts. J Periodontal Res 34: 277-281, 1999.
33. Ogawa T, Linz W, Stevenson M, Bruneau BG, Kuroski de Bold ML, Chen JH, Eid H, Scholkens BA, and de Bold AJ. Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production. Circulation 93: 2059-2067, 1996.
34. Oudot F, Grynberg A, and Sergiel JP. Eicosanoid synthesis in cardiomyocytes: influence of hypoxia, reoxygenation, and polyunsaturated fatty acids. Am J Physiol Heart Circ Physiol 268: H308-H315, 1995.
35. Palmer RM, Delday MI, McMillan DN, Noble BS, Bain P, and Maltin CA. Effects of the cyclo-oxygenase inhibitor, fenbufen, on clenbuterol-induced hypertrophy of cardiac and skeletal muscle of rats. Br J Pharmacol 101: 835-838, 1990.
36. Saito T, Rodger IW, Hu F, Shennib H, and Giaid A. Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction. Biochem Biophys Res Commun 273: 772-775, 2000.
37. Sanchez PL, Salgado LM, Ferreri NR, and Escalante B. Effect of cyclooxygenase-2 inhibition on renal function after renal ablation. Hypertension 34: 848-853, 1999.
38. Scheuren N, Jacobs M, Ertl G, and Schorb W. Cyclooxygenase-2 in myocardium stimulation by angiotensin-II in cultured cardiac fibroblasts and role at acute myocardial infarction. J Mol Cell Cardiol 34: 29-37, 2002.
39. Shinmura K, Tang XL, Wang Y, Xuan YT, Liu SQ, Takano H, Bhatnagar A, and Bolli R. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci USA 97: 10197-10202, 2000.
40. Smith WL, DeWitt DL, and Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69: 145-182, 2000.
41. Tardieu D, Jaeg JP, Deloly A, Corpet DE, Cadet J, and Petit CR. The COX-2 inhibitor nimesulide suppresses superoxide and 8-hydroxy-deoxyguanosine formation, and stimulates apoptosis in mucosa during early colonic inflammation in rats. Carcinogenesis 21: 973-976, 2000.
42. Tsuruda T, Boerrigter G, Huntley BK, Noser JA, Cataliotti A, Costello-Boerrigter LC, Chen HH, and Burnett JC Jr. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 91: 1127-1134, 2002.
43. Vane JR, Bakhle YS, and Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38: 97-120, 1998.
44. Wang JL, Cheng HF, Shappell S, and Harris RC. A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. Kidney Int 57: 2334-2342, 2000.
45. Williams C, Shattuck-Brandt RL, and DuBois RN. The role of COX-2 in intestinal cancer. Ann NY Acad Sci 889: 72-83, 1999.
46. Williams CS, Mann M, and DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18: 7908-7916, 1999.
47. Wong SC, Fukuchi M, Melnyk P, Rodger I, and Giaid A. Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure. Circulation 98: 100-103, 1998.
48. Yamamoto T, Kakar NR, Vina ER, Johnson PE, and Bing RJ. Effect of cyclooxygenase-2 inhibitor (celecoxib) on the infarcted heart in situ. Pharmacology 63: 28-33, 2001.
49. Yang F, Liu YH, Yang XP, Xu J, Kapke A, and Carretero OA. Myocardial infarction and cardiac remodelling in mice. Exp Physiol 87: 547-555, 2002.
50. Yang X, Ma N, Szabolcs MJ, Zhong J, Athan E, Sciacca RR, Michler RE, Anderson GD, Wiese JF, Leahy KM, Gregory S, and Cannon PJ. Upregulation of COX-2 during cardiac allograft rejection. Circulation 101: 430-438, 2000.
51. 2 kinin receptor gene knockout mice. Circ Res 88: 1072-1079, 2001.